SSA
CVAC

Schonfeld Strategic Advisors’s CureVac CVAC Stock Holding History

Schonfeld Strategic Advisors’s Portfolio CVAC Stock Details CVAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-93,600
Closed -$5.11M – 2208
2021
Q3 		$5.11M Buy
93,600
+65,100
+228% +$3.92M 0.05% 432
2021
Q2 		$2.09M Buy
+28,500
New +$2.85M 0.02% 691

Other funds holding CVAC

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Schonfeld Strategic Advisors's CVAC Position: Q1 2024 in Review

Schonfeld Strategic Advisors sold out of CureVac (CVAC) in Q1 2024, closing a stake of 275,300 shares — an estimated $1.16M sold.

Schonfeld Strategic Advisors first reported a position in CVAC in Q2 2021 and held it in 6 quarters. The position peaked at $1.16M in Q4 2023. 90 funds tracked by Wall St. Rank hold CVAC as of Q1 2024.

  • Schonfeld Strategic Advisors reported no remaining CureVac position as of Q1 2024 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 275,300 CureVac shares in Q1 2024, an estimated $1.16M.
  • Schonfeld Strategic Advisors first reported a position in CureVac in Q2 2021 and held it in 6 quarters.
  • Schonfeld Strategic Advisors's CureVac position peaked at $1.16M in Q4 2023.
  • 90 funds tracked by Wall St. Rank held CureVac as of Q1 2024.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2024, filed 15 May 2024.